These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 33020060)

  • 1. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalbavancin in the treatment of different gram-positive infections: a real-life experience.
    Bouza E; Valerio M; Soriano A; Morata L; Carus EG; Rodríguez-González C; Hidalgo-Tenorio MC; Plata A; Muñoz P; Vena A;
    Int J Antimicrob Agents; 2018 Apr; 51(4):571-577. PubMed ID: 29180276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter clinical experience of real life Dalbavancin use in gram-positive infections.
    Wunsch S; Krause R; Valentin T; Prattes J; Janata O; Lenger A; Bellmann-Weiler R; Weiss G; Zollner-Schwetz I
    Int J Infect Dis; 2019 Apr; 81():210-214. PubMed ID: 30794940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of disease including treatment with dalbavancin in a Spanish hospital: ECODAL ANALYSIS.
    Valerio M; Veintimilla C; Rodríguez C; de la Villa S; Sánchez-Somolinos M; Cerezales M; Crespo C; Rodríguez S; Adán I; Chamorro E; Rosselló I; Muñoz P
    J Med Econ; 2023; 26(1):463-472. PubMed ID: 36950932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.
    Morrisette T; Miller MA; Montague BT; Barber GR; McQueen RB; Krsak M
    J Antimicrob Chemother; 2019 Aug; 74(8):2405-2416. PubMed ID: 31322694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
    Petrakis V; Panagopoulos P; Papanas N
    Int J Low Extrem Wounds; 2020 Sep; 19(3):236-241. PubMed ID: 32500744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with dalbavancin use in various gram-positive infections within Aberdeen Royal Infirmary OPAT service.
    McSorley JC; Reyes D; Tonna I; Bateman V
    Infection; 2024 Apr; 52(2):567-576. PubMed ID: 38165594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital.
    Lueking R; Wei W; Mang NS; Ortwine JK; Meisner J
    Microbiol Spectr; 2023 Feb; 11(1):e0238522. PubMed ID: 36537818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalbavancin use in an academic medical centre and associated cost savings.
    Streifel AC; Sikka MK; Bowen CD; Lewis JS
    Int J Antimicrob Agents; 2019 Nov; 54(5):652-654. PubMed ID: 31398481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
    Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
    Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of dalbavancin in skin and soft tissue infections.
    Bassetti M; Peghin M; Carnelutti A; Righi E
    Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).
    Bai F; Aldieri C; Cattelan A; Raumer F; Di Meco E; Moioli MC; Tordato F; Morelli P; Borghi F; Rizzi M; Van Hauwermeiren E; Castelli F; Migliorino G; Menzaghi B; Rizzardini G; Saracino A; Cascio A; Puoti M; d'Arminio Monforte A; Marchetti G
    Expert Rev Anti Infect Ther; 2020 Dec; 18(12):1271-1279. PubMed ID: 32797758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of dalbavancin in France: a prospective, multicentre cohort study.
    Courjon J; Senneville E; Illes HG; Pavese P; Boutoille D; Daoud FC; Dunkel N; Tattevin P
    Int J Antimicrob Agents; 2023 Oct; 62(4):106945. PubMed ID: 37543122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.
    Poliseno M; Bavaro DF; Brindicci G; Luzzi G; Carretta DM; Spinarelli A; Messina R; Miolla MP; Achille TI; Dibartolomeo MR; Dell'Aera M; Saracino A; Angarano G; Favale S; D'Agostino C; Moretti B; Signorelli F; Taglietti C; Carbonara S
    Clin Drug Investig; 2021 May; 41(5):437-448. PubMed ID: 33884583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current trends in the real-life use of dalbavancin: report of a study panel.
    Durante-Mangoni E; Gambardella M; Iula VD; De Stefano GF; Corrado MF; Esposito V; Gentile I; Coppola N
    Int J Antimicrob Agents; 2020 Oct; 56(4):106107. PubMed ID: 32721599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
    Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.